In contrast, our data suggest that GSK5182, a selective ERRγ inverse agonist, attenuates NF-κB activity in MM cells without reducing body weight in treated mice, a preliminary but consistent indicator of tolerability. Here, NFKB1 is linked to Miyoshi myopathy.